1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

EU Fees Revision A ‘Once-In-A-Generation’ Chance To Solve Resource Challenges

 
• By Ian Schofield

COVID-19 and Brexit have put a great strain on the resources of the EU medicines regulatory system, but the planned review of the EU fee system could produce a system that is more flexible, efficient and better able to respond rapidly to emerging technologies and the needs of health care systems, says EFPIA.

EUFlagPills
The EU is changing the way it charges fees for drug regulatory services • Source: Shutterstock

Proposals to overhaul and simplify the EU’s complex fee framework, under which fees would be more transparent and reflect the actual costs of regulatory services, have been hailed by the R&D-based industry federation EFPIA as a chance to make the EU regulatory system more flexible, efficient and internationally competitive.

Many aspects of the fee proposals are “well aligned” with EFPIA’s “fundamental principles of transparency, fairness & proportionality, sustainability, simplicity,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

Only One ANDA Was Submitted To The US FDA During The Shutdown; It Should Have Been None

 
• By Derrick Gingery

The FDA told the Pink Sheet an ANDA managed to be submitted during a period when no new ANDAs could be accepted.

Obscure User Fee Provision Gives Generic Drug Sponsors More Time To Pay Fees Post-Shutdown

 
• By Derrick Gingery

ANDA sponsors received 20 days to pay fees associated with applications submitted during the government shutdown, while NDA and BLA sponsors only received five days.

GDUFA IV: US FDA Wants to ‘Streamline’ Formal Meeting Structure

 
• By Derrick Gingery

The FDA proposed changes to the formal meeting system for sponsors in the next generic drug user fee program cycle, in part to speed timelines.

Onshoring Incentives Among US FDA’s GDUFA IV Proposals

 
• By Derrick Gingery

During the first GDUFA IV negotiation session, industry representatives were unsure whether the FDA’s idea to create pathways for onshoring incentives fit the scope of the generic drug user fee program.

More from Pathways & Standards

GDUFA IV: US FDA Wants to ‘Streamline’ Formal Meeting Structure

 
• By Derrick Gingery

The FDA proposed changes to the formal meeting system for sponsors in the next generic drug user fee program cycle, in part to speed timelines.

Onshoring Incentives Among US FDA’s GDUFA IV Proposals

 
• By Derrick Gingery

During the first GDUFA IV negotiation session, industry representatives were unsure whether the FDA’s idea to create pathways for onshoring incentives fit the scope of the generic drug user fee program.

Eight African Agencies Finalizing Reliance Mechanism To Speed Drug Approvals

 
• By Neena Brizmohun

A new reliance pathway under which regulators will rely on each other’s assessment reports strengthens the goals of key continental health initiatives, including the newly formed African Medicines Agency.